AMS Biotechnology has further expanded its product range to help in the fight against COVID-19, with the introduction of a new range of SARS-CoV-2 antibodies and antigens to aid development of new immunoassay diagnostic kits. A suite of SARS-CoV-2 mutant spike and nucleocapsid antigens is now available. Perfect for use in a wide range of different antibody detection methods, these antigens are customizable and available in bulk. In addition, we have also introduced a new range of matched antibody pairs specifically designed and screened for antigen detection kit development. Verified against inactivated COVID-19 virus samples, these antibody pairs are ideal for development of diagnostic assays, including chemiluminescent immunoassays, ELISAs, and gold immunochromatographic assays [also known as lateral flow assays (LFAs)]. The sensitivity of these matched antibody pairs when used in a sandwich ELISA kit has been shown to be as low as 12 pg/mL. The virus titer, which was determined using an LFA, is as low as 102 cell culture infectious dose 50% (CCID50)/mL.